|
Novo is shaping a future beyond its Wegovy franchise as CEO Maziar Mike Doustdar looks to turn the drugmaker’s fortunes around.
|
 |
|
Backing for the approval comes from data in NewAmsterdam’s clinical development programme, including Phase III trials.
|
|
|
The facility is positioned to supply therapies for clinical and commercial use in 2027.
|
|
|
The deal is expected to close by the end of the 2026 financial year, subject to Telix shareholder and regulatory approvals.
|
|
|
mAbxience will lead the development and production of the biosimilar candidate at its manufacturing facilities in Argentina and Spain.
|
|
